AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 141 min read$ANIP

Cook Meredith sold $41K of ANIP

Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) sold 500 shares of ANI PHARMACEUTICALS INC (ANIP) at $81.84 on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Meredith
Published Jul 14, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ANIP
Neutral
high confidence
Mentioned
$ANIP
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale of 500 shares at $81.84 on 2026-07-13, with holdings after the trade of 77,390 shares.

02

Market read

Traders may briefly monitor insider activity, but a 10b5-1 sale of ~$40.9K is generally not a fundamental catalyst.

03

What to watch

The transaction size is small relative to typical institutional flows, and 10b5-1 plans are designed to reduce timing-based inference.

Relevance 2/10Novelty 3/10Timing: Filed on 2026-07-14 for a sale executed on 2026-07-13.

Background

This is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals, reported by an officer (SR. VP, General Counsel & SEC).

Company-level read

Ticker impact

$ANIPNeutralHigh confidence
Context

Meredith Cook, ANI Pharmaceuticals’ General Counsel, sold 500 shares on 2026-07-13 at $81.84 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact would be limited to intraday sentiment around the filing.

Evidence & confidence

The filing is a Form 4 open-market sale, explicitly under a pre-arranged 10b5-1 plan, and the disclosed transaction value is about $40.9K.

Market effects

Sector

No clear read-across to the biotech/pharma sector from a single planned insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even planned 10b5-1 sales can coincide with internal views on liquidity or risk, so some traders may still treat it as a mild negative sentiment signal.

Key entities

  • issuer
    ANI Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Meredith Cook

    Officer (SR. VP, General Counsel & SEC) who executed the sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$ANIPMed

ANI Pharmaceuticals revenue rises 25.9% to $266M

ANI Pharmaceuticals reported record Q2 2026 net revenue of $266.0 million, up 25.9% year over year. GAAP net income was $24.7 million and adjusted EBITDA rose 32.4% to $71.6 million. Cortrophin Gel revenue grew 43.5% to $117.1 million, but full-year Cortrophin guidance was cut to $520–$540 million. ANIP shares fell 5.53% to $78.06.

grafa.com3 min
AUG 7
$ANIPMed

ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue

ANI Pharmaceuticals’ Q2 2026 earnings call covered Cortrophin Gel gout expansion and guidance. CEO Nikhil Alwani said sales force reps expanded to 180 by end-June, with over 95% generating multiple patient cases. Full-year Cortrophin guidance was trimmed to $520-$540 million, citing first-half performance and factors beyond case counts. Operating leverage investment is expected to drive improved margins in 2027.

finance.yahoo.com4 min
AUG 7
$ANIPMed

ANI PHARMACEUTICALS INC (ANIP): Results of Operations and Financial Condition

ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 anip-20260807xexx991.htm EX-99.1 Document Exhibit 99.1 ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results • Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year • Purified Cortrophin ® Gel net revenues of $117.1 million, an

SEC EDGAR 8-K6 min